Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
PALO ALTO, Calif. - Guardant Health , Inc. (NASDAQ: NASDAQ:GH), a precision oncology company with a market capitalization of ...
Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of Birmingham researchers to discover proteins that have strong predictive potential ...
Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of ...
Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...
Dr. Guglietta: Yes. So, it's exactly the challenge. And what we are actually seeing is that at the moment, especially for ...
Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...
Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of Birmingham researchers to discover proteins that have strong predictive potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback